Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

Launched by CENTRE LEON BERARD · May 16, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on patients who have advanced or metastatic pancreatic cancer. The goal is to implement a special screening program that looks at the unique characteristics of each patient’s cancer before they start their first treatment. By understanding these characteristics, doctors hope to provide more personalized treatment options, which may include targeted therapies along with traditional chemotherapy.

To be eligible for this trial, participants must be at least 18 years old and have advanced pancreatic cancer that has not been treated with more than one prior chemotherapy for their current condition. They also need to have a tumor sample available from their original diagnosis. Patients should have a life expectancy of more than three months and a good performance status, which means they are generally able to carry out daily activities. If you choose to participate, you will undergo tests to help determine the best treatment plan tailored to your specific cancer. It’s important to note that this study is currently recruiting participants, and it aims to offer hope through personalized medicine for those facing this challenging diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patient \> 18 years
• • metastatic or advanced PDAC
• • Patient pretreated with no more than one prior systemic chemotherapy for metastatic/advanced disease (radiotherapy is not counted as a line of therapy).
• • Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.
• • Life expectancy \> 3 months
• • PS score 0 or 1.
• Exclusion Criteria:
• • Curative therapy available
• • Any condition contraindicated with blood sampling procedures required by the protocol.
• • Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
• • Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.